

Nonclinical studies of therapeutic radiopharmaceuticals for ovarian cancer based on nano-drug carriers for global market entry



ONCOLOGY		Preclinical
Product Type	Radiopharmaceuticals	
Indication	Ovarian cancer	
Target	Folate Receptor- α (FR- α)	
MoA(Mechanism of Action)	<ul style="list-style-type: none">- Our radiopharmaceutical merges folic acid with the radioisotope ruthenium-177 within nanoparticles.- It selectively attaches to the surface of ovarian cancer cells that overexpress the folate receptor (FR).- The radioisotope delivers targeted radiation, directly combating and eliminating the cancer cells.	
Competitiveness	<ul style="list-style-type: none">- ADC drugs (e.g., Elahere (ImmunoGen)- Radiopharmaceuticals (e.g., Pluvicto, Lutathera (Novartis AG))	
Development Stage	Nonclinical study	
Route of Administration	Intravenous (IV)	